Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition

Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet